Safety Considerations and When to Contact Your Provider Mild lightheadedness that resolves with sitting, hydration, or a small meal is typically not a sign of danger and often improves within days as your body stabilizes
His concern is structural: if compounding eligibility becomes a commercially viable alternative to the full drug approval pathway, pharmaceutical developers will have a financial incentive to bypass Phase III trials entirely
Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
#MalnutritionAwareness #ClinicalNutrition #NutritionRecovery #MedicalNutritionTherapy #PublicHealthNutrition #DietitianCare #EvidenceBasedNutrition #HealthOutcomes To view or add a comment, sign in New research published in Nature Communications indicates a potential association between common food preservatives and an increased risk of type 2 diabetes
Both clonidine and propranolol can interact with other medications, potentially altering their effects or increasing side effects
According to NICE guideline NG28, GLP-1 receptor agonists should be considered when: Triple therapy (metformin and two other oral drugs) is not effective, not tolerated, or contraindicated The patient has a BMI 35 kg/m (or lower in people of Black, Asian and other minority ethnic groups) and specific obesity-related comorbidities The patient has a BMI 40% reduction in non-HDL cholesterol GLP-1 receptor agonist for glycaemic control and weight management (with secondary lipid benefits) Ezetimibe if non-HDL cholesterol reduction is insufficient Lifestyle interventions addressing diet, exercise, and weight Monitoring and follow-up are essential components of cholesterol management
